Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Pancreatic Neoplasms 5Carcinoma, Hepatocellular 4Rectal Neoplasms 3Gallbladder Neoplasms 3Colonic Neoplasms 3Biliary Tract Neoplasms 3Melanoma 2Lung Neoplasms 2Breast Neoplasms 2Bile Duct Neoplasms 2Recurrence 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 10Gemcitabine 8Cisplatin 7Hepatectomy 6Fluorouracil 6Radiofrequency Ablation 5Liver Transplantation 5Irinotecan 5Capecitabine 5lenvatinib 4Paclitaxel 4Neoadjuvant Therapy 4Folfox protocol 4Cetuximab 4Aspirin 4tislelizumab 3Surgical Procedures, Operative 3Nivolumab 3Carboplatin 3titanium silicide 2durvalumab 2apatinib 2Trastuzumab 2S 1 (combination) 2Leucovorin 2Lamivudine 2Introns 2Ethiodized Oil 2Drug Therapy 2DNA, Mitochondrial 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × AZD 6244 × Gastrointestinal × Clear all
NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
57 enrolled
Gastrointestinal

Gallbladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡